BidaskClub Upgrades Uniqure (QURE) to “Hold”

Uniqure (NASDAQ:QURE) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, May 7th, BidAskClub reports.

A number of other research firms have also commented on QURE. Wells Fargo & Co upped their price target on Uniqure from $65.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, March 15th. HC Wainwright restated a “buy” rating and set a $73.00 target price (up previously from $60.00) on shares of Uniqure in a research report on Monday, February 11th. Robert W. Baird began coverage on Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $68.00 price target on shares of Uniqure in a research note on Friday, February 8th. Finally, Zacks Investment Research downgraded Uniqure from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 6th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $75.82.

Shares of Uniqure stock traded down $2.92 during trading on Tuesday, reaching $57.51. 433,300 shares of the company’s stock were exchanged, compared to its average volume of 479,109. The stock has a market capitalization of $2.34 billion, a P/E ratio of -24.58 and a beta of 0.99. Uniqure has a 1-year low of $21.98 and a 1-year high of $69.60. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. On average, research analysts forecast that Uniqure will post -3.07 earnings per share for the current year.

In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $58.38, for a total transaction of $467,040.00. Following the completion of the transaction, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at $24,620,597.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the transaction, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders have sold 82,922 shares of company stock valued at $5,223,849 over the last ninety days. 2.91% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Harvest Group Wealth Management LLC purchased a new stake in shares of Uniqure in the first quarter worth $26,000. Legal & General Group Plc raised its position in Uniqure by 264.2% during the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 700 shares in the last quarter. Kore Private Wealth LLC purchased a new stake in Uniqure during the first quarter valued at about $30,000. Pearl River Capital LLC purchased a new stake in Uniqure during the first quarter valued at about $32,000. Finally, SEI Investments Co purchased a new stake in Uniqure during the first quarter valued at about $35,000. 60.12% of the stock is owned by hedge funds and other institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.